Exact Sciences Highlights Advances in MRD and Multi-Cancer Early Detection at AACR 2026
Exact Sciences Corp. is set to present significant new data at the AACR Annual Meeting 2026, underscoring its continued leadership in cancer diagnostics and precision oncology. The company announced four key presentations that focus on advancements in molecular residual disease (MRD) detection and multi-cancer early detection (MCED), two rapidly evolving areas that are reshaping how cancer is detected and managed.
The annual meeting, scheduled to take place from April 17 to April 22, 2026, in San Diego, California, will serve as a platform for Exact Sciences to showcase data from its innovative diagnostic portfolio, including the Oncodetect® MRD test and the Cancerguard® MCED test. These presentations collectively highlight the company’s strategy of leveraging molecular insights to enable earlier detection, improved risk assessment, and more personalized treatment monitoring.
Strengthening the Role of MRD in Cancer Care
A major focus of Exact Sciences’ presentations is the expanding role of tumor-informed MRD testing, particularly in aggressive cancers such as triple-negative breast cancer (TNBC). MRD testing uses circulating tumor DNA (ctDNA) to detect traces of cancer that may remain in the body after treatment, offering clinicians a powerful tool to assess treatment response and predict recurrence.
One of the featured studies evaluates the performance of the Oncodetect® test in patients with early-stage TNBC. This research is based on a sub-study of the NSABP B-59/GBG-96-GeparDouze clinical trial, a well-known investigation in the breast cancer research community.
The findings demonstrate that ctDNA status measured after neoadjuvant therapy (treatment given before surgery) is strongly associated with key clinical outcomes. Specifically, patients with detectable ctDNA prior to surgery were more likely to experience incomplete pathological response and had a higher risk of distant recurrence. Conversely, patients without detectable ctDNA showed better outcomes, including higher rates of pathologic complete response (pCR).
These results suggest that MRD testing can serve as an early indicator of treatment resistance. By identifying patients at higher risk of recurrence before surgery, clinicians may be able to adjust treatment strategies more effectively. This has important implications for improving outcomes in TNBC, a subtype of breast cancer known for its aggressive nature and limited targeted treatment options.
Expanding Applications in Breast and Colorectal Cancer
In addition to TNBC, Exact Sciences is also presenting data on the broader utility of ctDNA and genomic profiling across breast and colorectal cancers. Another study explores the value of identifying actionable genetic alterations through comprehensive tumor profiling.
The research shows that nearly all patients included in the study had at least one detectable genomic alteration when analyzed using ctDNA-based approaches. Importantly, approximately half of these alterations were linked to therapies that are already approved by regulatory authorities.
This highlights the growing importance of integrating genomic data into routine cancer care. By identifying actionable mutations, clinicians can better match patients with targeted therapies, improving treatment precision and potentially enhancing outcomes.
Furthermore, the use of ctDNA as a minimally invasive testing method offers practical advantages over traditional tissue biopsies. It allows for repeated sampling over time, enabling continuous monitoring of tumor evolution and treatment response. This dynamic approach aligns with the broader trend toward personalized medicine, where treatment decisions are guided by real-time molecular insights.
Advancing Multi-Cancer Early Detection
Another key pillar of Exact Sciences’ research presented at AACR 2026 is multi-cancer early detection (MCED). Unlike traditional screening methods that focus on a single cancer type, MCED tests are designed to detect multiple cancers simultaneously from a single blood sample.
The Cancerguard® test, developed by Exact Sciences, represents a multi-biomarker approach that combines DNA methylation patterns and protein biomarkers to identify cancer signals in the body. The company is presenting updated data on an optimized version of its MCED classifier, referred to as the methylation-protein (MP V2) model.
The results indicate that the updated classifier demonstrates improved sensitivity for detecting early-stage cancers compared to its previous version. Importantly, this increase in sensitivity does not come at the cost of specificity, meaning the test maintains a low rate of false positives.
Early detection is critical in cancer care, as cancers identified at earlier stages are generally more treatable and associated with better survival outcomes. By improving the ability to detect cancers before symptoms arise, MCED tests like Cancerguard® have the potential to significantly impact public health.
The Power of Multi-Biomarker Integration
Another presentation further explores the scientific foundation behind the Cancerguard® test by examining the complementary roles of methylation and protein biomarkers in cancer detection.
The findings reveal that these two biomarker classes contribute independently and synergistically to cancer signal detection. DNA methylation patterns provide insights into gene regulation changes associated with cancer, while protein biomarkers reflect alterations in biological processes occurring in the body.
By combining these distinct types of data, the test achieves a more comprehensive view of cancer biology. This multi-dimensional approach enhances the ability to detect cancer signals, particularly in early-stage disease where biomarkers may be less pronounced.
The study emphasizes that no single biomarker type is sufficient on its own. Instead, integrating multiple data sources improves overall test performance and reliability. This supports the broader industry trend toward multi-omic approaches in diagnostics, which aim to capture the complexity of cancer through diverse biological signals.
A Unified Strategy for Early Detection and Monitoring
Exact Sciences’ presentations at AACR 2026 reflect a cohesive strategy that spans the entire cancer care continuum—from early detection to post-treatment monitoring. By combining MRD testing with MCED technologies, the company aims to provide clinicians with a comprehensive toolkit for managing cancer more effectively.
According to the company’s leadership, the goal is to use molecular information to guide decision-making at every stage of the disease. This includes identifying cancer earlier, assessing treatment response, detecting residual disease, and monitoring for recurrence.
The integration of tumor-informed ctDNA analysis with multi-biomarker detection approaches represents a significant advancement in oncology diagnostics. It enables a more precise understanding of cancer biology and how it evolves over time, which is critical for developing personalized treatment strategies.
Looking Ahead
The data being presented at AACR 2026 reinforces Exact Sciences’ position at the forefront of cancer diagnostics innovation. As MRD and MCED technologies continue to evolve, they are expected to play an increasingly important role in clinical practice.
For patients, these advancements could translate into earlier diagnoses, more tailored treatments, and improved outcomes. For clinicians, they offer new tools to make more informed decisions based on real-time molecular data.
While challenges remain—such as ensuring accessibility, affordability, and integration into healthcare systems—the progress demonstrated by Exact Sciences highlights the transformative potential of molecular diagnostics in oncology.
As research continues and more data becomes available, the combination of MRD testing and multi-cancer early detection could redefine the standard of care, moving the field closer to the ultimate goal of detecting cancer early and managing it more effectively throughout its course.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company’s growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Cancerguard® for blood-based analysis of molecular information across multiple cancers and Oncodetect® for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
